Stock Scorecard
Stock Summary for Poseida Therapeutics Inc (PSTX) - $2.67 as of 11/19/2024 10:45:57 AM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PSTX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PSTX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PSTX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PSTX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for PSTX (27 out of 90)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 5 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 3 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 5 |
Trading Volume (Max of 10) | 5 |
Price to Earnings (Max of 10) | 0 |
Latest News for for PSTX
Financial Details for PSTX
Company Overview |
|
---|---|
Ticker | PSTX |
Company Name | Poseida Therapeutics Inc |
Country | USA |
Description | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with high unmet medical needs. The company is headquartered in San Diego, California. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 2.67 |
Price 4 Years Ago | 10.97 |
Last Day Price Updated | 11/19/2024 10:45:57 AM EST |
Last Day Volume | 412,949 |
Average Daily Volume | 516,922 |
52-Week High | 4.27 |
52-Week Low | 1.87 |
Last Price to 52 Week Low | 42.78% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 120.49 |
Sector PE | 40.32 |
5-Year Average PE | -4.16 |
Free Cash Flow Ratio | 1.13 |
Industry Free Cash Flow Ratio | 15.59 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 3.20 |
Total Cash Per Share | 2.37 |
Book Value Per Share Most Recent Quarter | 0.90 |
Price to Book Ratio | 3.08 |
Industry Price to Book Ratio | 5.50 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 1.73 |
Industry Price to Sales Ratio Twelve Trailing Months | 20.11 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 3 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 97,465,000 |
Market Capitalization | 260,231,550 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -92.81% |
Reported EPS 12 Trailing Months | -0.63 |
Reported EPS Past Year | -0.36 |
Reported EPS Prior Year | -1.39 |
Net Income Twelve Trailing Months | -60,729,000 |
Net Income Past Year | -123,400,000 |
Net Income Prior Year | -64,000,000 |
Quarterly Revenue Growth YOY | 667.00% |
5-Year Revenue Growth | 0.00% |
Operating Margin Twelve Trailing Months | 0.28 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 230,900,000 |
Total Cash Past Year | 212,200,000 |
Total Cash Prior Year | 282,500,000 |
Net Cash Position Most Recent Quarter | 172,104,000 |
Net Cash Position Past Year | 153,610,000 |
Long Term Debt Past Year | 58,590,000 |
Long Term Debt Prior Year | 58,250,000 |
Total Debt Most Recent Quarter | 58,796,000 |
Equity to Debt Ratio Past Year | 0.64 |
Equity to Debt Ratio Most Recent Quarter | 0.60 |
Total Stockholder Equity Past Year | 103,701,000 |
Total Stockholder Equity Prior Year | 187,595,000 |
Total Stockholder Equity Most Recent Quarter | 87,211,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -17,159,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.18 |
Free Cash Flow Past Year | -95,266,000 |
Free Cash Flow Prior Year | -30,696,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.16 |
MACD Signal | 0.10 |
20-Day Bollinger Lower Band | 2.17 |
20-Day Bollinger Middle Band | 2.90 |
20-Day Bollinger Upper Band | 3.62 |
Beta | 0.54 |
RSI | 47.42 |
50-Day SMA | 3.39 |
150-Day SMA | 0.00 |
200-Day SMA | 4.67 |
System |
|
Modified | 11/19/2024 10:46:43 AM EST |